Loading...
Zydus Lifesciences Limited — Apixaban Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #5 for Apixaban · $8.1M export value · DGFT Verified
Zydus Lifesciences Limited is the #5 Indian exporter of Apixaban with $8.1M in export value and 194 verified shipments. Zydus Lifesciences Limited holds a 4.5% market share in Apixaban exports across 11 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $3.4M | 125 | 74.2% |
| SRI LANKA | $270.6K | 19 | 5.9% |
| SOUTH AFRICA | $253.5K | 8 | 5.5% |
| PHILIPPINES | $247.3K | 20 | 5.4% |
| VIETNAM, DEMOCRATIC REP. OF | $136.8K | 5 | 3.0% |
| UNITED KINGDOM | $126.3K | 3 | 2.7% |
| MAURITIUS | $58.0K | 2 | 1.3% |
| KENYA | $47.8K | 5 | 1.0% |
| HONDURAS | $17.9K | 1 | 0.4% |
| FRANCE | $15.6K | 4 | 0.3% |
Zydus Lifesciences Limited exports Apixaban to 12 countries. The largest destination is BRAZIL accounting for 74.2% of Zydus Lifesciences Limited's Apixaban shipments, followed by SRI LANKA (5.9%) and SOUTH AFRICA (5.5%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BRAINFARMA INDUSTRIA QUIMICA E | BRAZIL | $2.4M | 66 |
| ZYDUS NIKKHO FARMACEUTICA LTDA | BRAZIL | $781.2K | 34 |
| SUNSHINE HEALTHCARE LANKA LIMITED | SRI LANKA | $270.6K | 19 |
| COSMED IND. DE COSM. MED SA | BRAZIL | $268.6K | 25 |
| ZYDUS HEALTHCARE PHILIPPINES INC. | PHILIPPINES | $221.1K | 16 |
| HAPHARCO J.S.C. BRANCH | VIETNAM, DEMOCRATIC REP. OF |
India exported $85.0M worth of Apixaban through 4,492 shipments from 171 suppliers to 98 countries, serving 371 buyers globally. Zydus Lifesciences Limited contributes $8.1M to this total, accounting for 4.5% of India's Apixaban exports. Zydus Lifesciences Limited ships Apixaban to 12 countries through 16 buyers.
Zydus Lifesciences Limited's average Apixaban shipment value is $41.7K per consignment, based on 194 shipments totaling $8.1M. The largest destination is BRAZIL (74.2% of Zydus Lifesciences Limited's Apixaban exports).
Zydus Lifesciences Limited ranks #5 among 171 Indian Apixaban exporters with a 4.5% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($18.7M), APOTEX RESEARCH PRIVATE LIMITED ($18.1M), SANDOZ PRIVATE LIMITED ($15.6M). Zydus Lifesciences Limited processed 194 shipments to 11 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| APIXABAN 5MG TAB 60 S SALE BRAINFARMA (A | $400.0K | 8 |
| APIXABAN 2.5MG TAB 20 S SALE BRAINFARMA | $241.9K | 6 |
| APIXABAN 5MG TAB 20 S SALE BRAINFARMA (A | $201.1K | 6 |
| APIXABAN 2.5MG TAB 60S SALE BRAINFARMA(APIXABAN) DETAILS AS PER INVOICE | $200.0K | 4 |
| APIXABAN 2.5MG TAB 60 S SALE BRAINFARMA | $145.0K | 4 |
| APIXABAN 5MG TAB 60S SALE BRAINFARMA (APIXABAN) AS PER INVOICENOS | $102.2K | 3 |
| APIXABAN 2.5MG TAB 60 S SALE BRAINFARMA( | $100.0K | 2 |
| APIXABAN 5MG TABLET 60S SALE BRAZIL | $100.0K | 2 |
| APIXABAN 2.5MG TAB 60S SALE BRAINFARMA(APIXABAN) AS PER INVOICE |
What Zydus Lifesciences Limited must comply with to export Apixaban to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | APOTEX RESEARCH PRIVATE LIMITED | $18.1M | 361 | 2 | $50.0K |
| 4 | SANDOZ PRIVATE LIMITED | $15.6M | 500 | 8 | $31.2K |
| 5 | ZYDUS LIFESCIENCES LIMITED ★ | $8.1M | 194 | 11 | $41.7K |
| 1 | MACLEODS PHARMACEUTICALS LTD | $4.3M | 85 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 724 | 16.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 674 | 15.0% |
| DELHI AIR CARGO ACC (INDEL4) | 607 | 13.5% |
| DELHI AIR | 364 | 8.1% |
| MUNDRA SEA | 146 | 3.3% |
| Bombay Air | 134 | 3.0% |
| JNPT/ NHAVA SHEVA SEA | 131 | 2.9% |
| AHEMDABAD AIR ACC (INAMD4) | 129 | 2.9% |
Zydus Lifesciences Limited also exports these cardiovascular products. Each links to the detailed product page.
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Apixaban, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Apixaban — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Apixaban exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
| $136.8K |
| 5 |
| ZYDUS HEALTHCARE SA (PTY) LTD | SOUTH AFRICA | $134.9K | 4 |
| ZYDUS PHARMACEUTICALS UK LTD | UNITED KINGDOM | $126.3K | 3 |
| ZYDUS HEALTHCARE SA (PTY) LIMITED | SOUTH AFRICA | $118.6K | 4 |
| FTM (MAURITIUS) LTD. | MAURITIUS | $58.0K | 2 |
Zydus Lifesciences Limited supplies Apixaban to 16 buyers globally. The largest buyer is BRAINFARMA INDUSTRIA QUIMICA E (BRAZIL), followed by ZYDUS NIKKHO FARMACEUTICA LTDA (BRAZIL) and SUNSHINE HEALTHCARE LANKA LIMITED (SRI LANKA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| $100.0K |
| 2 |
| APIXABAN 5MG TAB 20S SALE BRAINFARMA (APIXABAN) AS PER INVOICE | $100.0K | 2 |
Zydus Lifesciences Limited exports 128 distinct Apixaban formulations including tablets, capsules, syrups, and combination drugs. The top formulation is APIXABAN 5MG TAB 60 S SALE BRAINFARMA (A with 8 shipments worth $400.0K.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 9 |
| $50.0K |
| 8 | UNISON PHARMACEUTICALS PRIVATE LIMITED | $3.9M | 114 | 5 | $34.2K |
Zydus Lifesciences Limited ranks #5 among 171 Indian Apixaban exporters. Average shipment value of $41.7K compared to the market average of $497.1K. The closest competitors by value are APOTEX RESEARCH PRIVATE LIMITED and SANDOZ PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 98+ countries, 371+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Apixaban. For current shipment-level data, contact TransData Nexus.